NK cells are the crucial antitumor mediators when STAT3-mediated immunosuppression is blocked in hepatocellular carcinoma

Journal of Immunology

Volumn 193, Issue 4, 2014, Pages 2016-2023

  Sui, Qiangjun ^a   Zhang, Jian ^a   Sun, Xiaoxia ^a   Zhang, Cai ^a   Han, Qiuju ^a   Tian, Zhigang ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 10; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INNATE IMMUNITY; LIVER CELL CARCINOMA; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ADOPTIVE TRANSFER; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; IMMUNE TOLERANCE; IMMUNITY, INNATE; INTERLEUKIN-10; KILLER CELLS, NATURAL; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; OLIGODEOXYRIBONUCLEOTIDES; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 84905989027     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302389     Document Type: Article

References (35)

1. Hann, H. W. , J. Lee, A. Bussard, C. Liu, Y. R. Jin, K. Guha, M. M. Clayton, K. Ardlie, M. J. Pellini, and M. A. Feitelson. 2004. Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma. Cancer Res. 64: 7329-7335.
2. Ormandy, L. A. , T. Hillemann, H. Wedemeyer, M. P. Manns, T. F. Greten, and F. Korangy. 2005. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 65: 2457-2464.
3. Li, T. , Y. Yang, X. Hua, G. Wang, W. Liu, C. Jia, Y. Tai, Q. Zhang, and G. Chen. 2012. Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO. Cancer Lett. 318: 154-161.
4. Wei, D. , X. Le, L. Zheng, L. Wang, J. A. Frey, A. C. Gao, Z. Peng, S. Huang, H. Q. Xiong, J. L. Abbruzzese, and K. Xie. 2003. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22: 319-329.
5. Yu, H. , M. Kortylewski, and D. Pardoll. 2007. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7: 41-51.
6. Sun, X. , J. Zhang, L. Wang, and Z. Tian. 2008. Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Lett. 262: 201-213.
7. Ihara, S. , H. Kida, H. Arase, L. P. Tripathi, Y. A. Chen, T. Kimura, M. Yoshida, Y. Kashiwa, H. Hirata, R. Fukamizu, et al. 2012. Inhibitory roles of signal transducer and activator of transcription 3 in antitumor immunity during carcinogen-induced lung tumorigenesis. Cancer Res. 72: 2990-2999.
8. Kortylewski, M. , and H. Yu. 2008. Role of Stat3 in suppressing anti-tumor immunity. Curr. Opin. Immunol. 20: 228-233.
9. Jenkins, B. J. , A. W. Roberts, C. J. Greenhill, M. Najdovska, T. Lundgren-May, L. Robb, D. Grail, and M. Ernst. 2007. Pathologic consequences of STAT3 hyperactivation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis. Blood 109: 2380-2388.
10. Radaeva, S. , R. Sun, H. N. Pan, F. Hong, and B. Gao. 2004. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 39: 1332-1342.
11. Jayaraman, P. , F. Parikh, E. Lopez-Rivera, Y. Hailemichael, A. Clark, G. Ma, D. Cannan, M. Ramacher, M. Kato, W. W. Overwijk, et al. 2012. Tumorexpressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J. Immunol. 188: 5365-5376.
12. Yu, H. , and R. Jove. 2004. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer 4: 97-105.
13. Sumimoto, H. , F. Imabayashi, T. Iwata, and Y. Kawakami. 2006. The BRAFMAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med. 203: 1651-1656.
14. Wang, T. , G. Niu, M. Kortylewski, L. Burdelya, K. Shain, S. Zhang, R. Bhattacharya, D. Gabrilovich, R. Heller, D. Coppola, et al. 2004. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10: 48-54.
15. Nefedova, Y. , M. Huang, S. Kusmartsev, R. Bhattacharya, P. Cheng, R. Salup, R. Jove, and D. Gabrilovich. 2004. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 172: 464-474.
16. Burdelya, L. , M. Kujawski, G. Niu, B. Zhong, T. Wang, S. Zhang, M. Kortylewski, K. Shain, H. Kay, J. Djeu, et al. 2005. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J. Immunol. 174: 3925-3931.
17. Kortylewski, M. , M. Kujawski, T. Wang, S. Wei, S. Zhang, S. Pilon-Thomas, G. Niu, H. Kay, J. Mulé, W. G. Kerr, et al. 2005. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11: 1314-1321.
18. Shen, J. , R. Li, and G. Li. 2009. Inhibitory effects of decoy-ODN targeting activated STAT3 on human glioma growth in vivo. In Vivo 23: 237-243.
19. Zhang, X. , J. Zhang, L. Wang, H. Wei, and Z. Tian. 2007. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer 7: 149.
20. Shultz, L. D. , P. A. Schweitzer, S. W. Christianson, B. Gott, I. B. Schweitzer, B. Tennent, S. McKenna, L. Mobraaten, T. V. Rajan, D. L. Greiner, et al. 1995. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J. Immunol. 154: 180-191.
21. Boccaccio, C. , M. Andò, L. Tamagnone, A. Bardelli, P. Michieli, C. Battistini, and P. M. Comoglio. 1998. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 391: 285-288.
22. Leong, P. L. , G. A. Andrews, D. E. Johnson, K. F. Dyer, S. Xi, J. C. Mai, P. D. Robbins, S. Gadiparthi, N. A. Burke, S. F. Watkins, and J. R. Grandis. 2003. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc. Natl. Acad. Sci. USA 100: 4138-4143.
23. Segre, J. A. , J. L. Nemhauser, B. A. Taylor, J. H. Nadeau, and E. S. Lander. 1995. Positional cloning of the nude locus: genetic, physical, and transcription maps of the region and mutations in the mouse and rat. Genomics 28: 549-559.
24. Grégoire, C. , L. Chasson, C. Luci, E. Tomasello, F. Geissmann, E. Vivier, and T. Walzer. 2007. The trafficking of natural killer cells. Immunol. Rev. 220: 169-182.
25. Vivier, E. 2006. What is natural in natural killer cells? Immunol. Lett. 107: 1-7.
26. Carreras, J. , A. Lopez-Guillermo, B. C. Fox, L. Colomo, A. Martinez, G. Roncador, E. Montserrat, E. Campo, and A. H. Banham. 2006. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 108: 2957-2964.
27. Wang, H. Y. , D. A. Lee, G. Peng, Z. Guo, Y. Li, Y. Kiniwa, E. M. Shevach, and R. F. Wang. 2004. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 20: 107-118.
28. Liu, V. C. , L. Y. Wong, T. Jang, A. H. Shah, I. Park, X. Yang, Q. Zhang, S. Lonning, B. A. Teicher, and C. Lee. 2007. Tumor evasion of the immune system by converting CD4+CD252 T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J. Immunol. 178: 2883-2892.
29. Yang, Z. , B. Zhang, D. Li, M. Lv, C. Huang, G. X. Shen, and B. Huang. 2010. Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model. PLoS One 5: e8922.
30. Fernandez, N. C. , A. Lozier, C. Flament, P. Ricciardi-Castagnoli, D. Bellet, M. Suter, M. Perricaudet, T. Tursz, E. Maraskovsky, and L. Zitvogel. 1999. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med. 5: 405-411.
31. Kennedy, R. , and E. Celis. 2008. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol. Rev. 222: 129-144.
32. Dunn, G. P. , A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3: 991-998.
33. Pivarcsi, A. , A. M̈uller, A. Hippe, J. Rieker, A. van Lierop, M. Steinhoff, S. Seeliger, R. Kubitza, U. Pippirs, S. Meller, et al. 2007. Tumor immune escape by the loss of homeostatic chemokine expression. Proc. Natl. Acad. Sci. USA 104: 19055-19060.
34. Brady, J. , S. Carotta, R. P. Thong, C. J. Chan, Y. Hayakawa, M. J. Smyth, and S. L. Nutt. 2010. The interactions of multiple cytokines control NK cell maturation. J. Immunol. 185: 6679-6688.
35. Smyth, M. J. , M. W. Teng, J. Swann, K. Kyparissoudis, D. I. Godfrey, and Y. Hayakawa. 2006. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol. 176: 1582-1587.